Literature DB >> 10702697

Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines.

M Nessling1, M A Kern, D Schadendorf, P Lichter.   

Abstract

The reason why human malignant melanomas respond poorly to chemotherapy is not known. In an attempt to identify genes responsible for such resistance or sensitivity to therapeutic drugs, we studied the parental human melanoma cell line MeWo, as well as eight drug-resistant sublines of MeWo. These have low and high levels of resistance to four chemotherapeutic drugs with different modes of action: Vindesine, cisplatin, fotemustine and etoposide. Comparative genomic hybridizations with genomic DNA from these cell lines as probes revealed a number of chromosome gains and losses which occurred upon selective pressure during development of the sublines. The MeWo subline with high resistance to the topoisomerase II inhibitor, etoposide, exhibited the highest number of acquired chromosome imbalances. Interestingly, the two lines with high resistance to cisplatin and fotemustine, respectively, shared three additional imbalances, loss of 9p, loss of distal 12p and gain on distal 15q. The importance of these coincident imbalances is discussed. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10702697     DOI: 10.1159/000015451

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  3 in total

1.  BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.

Authors:  Rizwan Haq; Satoru Yokoyama; Elena B Hawryluk; Göran B Jönsson; Dennie Tompers Frederick; Kevin McHenry; Dale Porter; Thanh-Nga Tran; Kevin T Love; Robert Langer; Daniel G Anderson; Levi A Garraway; Lyn McDivitt Duncan; Donald L Morton; Dave S B Hoon; Jennifer A Wargo; Jun S Song; David E Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-27       Impact factor: 11.205

2.  Cancer biomarker discovery: the entropic hallmark.

Authors:  Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

3.  Current awareness on comparative and functional genomics.

Authors: 
Journal:  Yeast       Date:  2000-09-30       Impact factor: 3.239

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.